These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22573857)

  • 1. Entecavir treatment of chronic hepatitis D.
    Kabaçam G; Onder FO; Yakut M; Seven G; Karatayli SC; Karatayli E; Savas B; Idilman R; Bozdayi AM; Yurdaydin C
    Clin Infect Dis; 2012 Sep; 55(5):645-50. PubMed ID: 22573857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
    Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
    Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus concentrations in serum determined by sensitive quantitative assays in patients with established chronic hepatitis delta virus infection.
    Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Zukeran H
    J Med Virol; 2001 Nov; 65(3):478-84. PubMed ID: 11596082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
    Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
    Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine for chronic delta hepatitis.
    Lau DT; Doo E; Park Y; Kleiner DE; Schmid P; Kuhns MC; Hoofnagle JH
    Hepatology; 1999 Aug; 30(2):546-9. PubMed ID: 10421666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation.
    Mederacke I; Filmann N; Yurdaydin C; Bremer B; Puls F; Zacher BJ; Heidrich B; Tillmann HL; Rosenau J; Bock CT; Savas B; Helfritz F; Lehner F; Strassburg CP; Klempnauer J; Wursthorn K; Lehmann U; Manns MP; Herrmann E; Wedemeyer H
    J Hepatol; 2012 Jan; 56(1):115-22. PubMed ID: 21762665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D.
    Schaper M; Rodriguez-Frias F; Jardi R; Tabernero D; Homs M; Ruiz G; Quer J; Esteban R; Buti M
    J Hepatol; 2010 May; 52(5):658-64. PubMed ID: 20346531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study.
    Niro GA; Ciancio A; Tillman HL; Lagget M; Olivero A; Perri F; Fontana R; Little N; Campbell F; Smedile A; Manns MP; Andriulli A; Rizzetto M
    Aliment Pharmacol Ther; 2005 Aug; 22(3):227-32. PubMed ID: 16091060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis.
    Zachou K; Yurdaydin C; Drebber U; Dalekos GN; Erhardt A; Cakaloglu Y; Degertekin H; Gurel S; Zeuzem S; Bozkaya H; Schlaphoff V; Dienes HP; Bock TC; Manns MP; Wedemeyer H;
    Liver Int; 2010 Mar; 30(3):430-7. PubMed ID: 19840253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
    Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
    N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
    Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
    N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of disease activity in patients of chronic hepatitis B virus, with and without superinfection with hepatitis D virus; an experience at tertiary care centre.
    Das K; Ali H; Mahmood T; Munir SM; Ahmed T; Farooq MU
    J Ayub Med Coll Abbottabad; 2008; 20(2):39-42. PubMed ID: 19385455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B and D viruses replication interference: Influence of hepatitis B genotype.
    Madejón A; Romero M; Hernández Á; García-Sánchez A; Sánchez-Carrillo M; Olveira A; García-Samaniego J
    World J Gastroenterol; 2016 Mar; 22(11):3165-74. PubMed ID: 27003993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b.
    Erhardt A; Gerlich W; Starke C; Wend U; Donner A; Sagir A; Heintges T; Häussinger D
    Liver Int; 2006 Sep; 26(7):805-10. PubMed ID: 16911462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.